The in vitro characterization of inhibitory drug-drug interactions involving UDP-glucuronosyltransferase

Enzyme- and Transporter-Based Drug-Drug Interactions: Progress and Future Challenges

Volumn , Issue , 2010, Pages 217-236

  Miners, John O ^a   Polasek, Thomas M ^a   Mackenzie, Peter I ^a   Knights, Kathleen M ^a  

^a FLINDERS UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 79952831126     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-4419-0840-7_8     Document Type: Chapter

References (58)

1. Ammon S, Von Richter O, Hofmann U, Thon K-P, Eichelbaum M and Mikus G (2000) In vitro interaction of codeine and diclofenac. Drug Metab Disp 28:1149-1152.
2. Austin RP, Barton P, Cockroft SL, Wenlock MC and Riley RJ (2002) The influence of non-specific microsomal binding on apparent intrinsic clearance, and its prediction from physicochemical properties. Drug Metab Disp 30:1497-1503.
3. Bauman JN, Goosen TC, Tugnait M, Peterkin V, Hurst DI, Menning LC, Milad M, Court MH and Williams JA (2005) UDP-Glucuronosyltransferase 2B7 is the major enzyme responsible for gemcabene glucuronidation in human liver microsomes. Drug Metab Disp 33:1349-1354.
4. Benoit-Biancamano M-O, Connelly J, Villeneuve L, Caron P and Guillemette C (2009) Deferiprone glucuronidation by human tissues and recombinant UDP-glucuronosyltransferase 1A6: an in vitro investigation of genetic and splice variants. Drug Metab Disp 37:322-329.
5. Boase S and Miners JO (2002) In vitro - in vivo correlations for drugs eliminated by glucuronidation: investigations with the model substrate zidovudine. Br J Clin Pharmacol 54:493-503.
6. Boyd MA, Srasuebkul P, Ruxrunggtham K, Mackenzie PI, Uchaipichat V, Stek M, Lange JMA, Phanuphak P, Cooper DA, Udomuksorn W and Miners JO (2006) Relationship between hyperbilirubinemia and UDP-glucuronosyltransferase 1 A1 polymorphism in HIV-infected Thai patients treated with indinavir. Pharmacogenet Genomics 16:321-329.
7. Bowalgaha K, Elliot DJ, Mackenzie PI, Knights KM and Miners JO (2007) The glucuronidation of A4-3-keto-hydroxysteroids by human liver microsomal UDP-glucuronosyltransferases: 6a- and 21-hydroxyprogesterone are metabolized selectively by UGT2B7. Drug Metab Disp 35:363-370.
8. Brown HS, Griffin M and Houston JB (2007) Evaluation of cryopreserved human hepatocytes as an alternative in vitro system to microsomes for the prediction of metabolic clearance. Drug Metab Disp 35:293-301.
9. Brown HS, Ito K, Galetin A and Houston JB (2005) Prediction of in vivo drug - drug interactions from in vitro data: impact of incorporating parallel pathways of drug elimination and inhibitor absorption rate constant. Br J Clin Pharmacol 60:508-518.
10. Corona G, Vaccher E, Sandron S, Sartor I, Tirelli U, Innocenti F and Toffoli G (2008) Lopinavirritonavir dramatically affects the pharmacokinetics of irinotecan in HIV patients with Kaposi's sarcoma. Clin Pharmacol Ther 83:601-606.
11. Court MH (2005) Isoform-selective probe substrates for in vitro studies of human UDP-glucuronosyltransferases. Methods Enzymol 400:104-116.
12. Court MH, Duan SX, Von Moltke LL, Greenblatt DJ, Patten CJ, Miners JO and Mackenzie PI (2001) Interindividual variability in acetaminophen glucuronidation by human liver microsomes: identification of relevant acetaminophen UDP-glucuronosyltransferase isoforms. J Pharmacol Exp Ther 299:998-1006.
13. Delaforge M, Pruvost A, Perrin L and André F (2005) Cytochrome P450-mediated oxidation of glucuronide derivatives: example of estradiol-17β-glucuronide oxidation to 2-hydroxyestradiol-17β- glucuronide by CYP 2C8. Drug Metab Dispos 33:466-473.
14. Engtrakul JJ, Foti RS, Strelevitz TJ and Fisher MB (2005) Altered AZT glucuronidation kinetics in liver microsomes as an explanation for underprediction of in vivo clearance. Drug Metab Disp 33:1621-1627.
15. Ethell BT, Anderson GD and Burchell B (2003) The effect of valproic acid on drug and steroid glucuronidation by expressed UDP-glucuronosyltransferases. Biochem Pharmacol 65:1441-1449.
16. Fisher MB, Campanale K, Ackermann BL, Vandenbranden M and Wrighton SA (2000) In vitro glucuronidation using human liver microsomes and the pore-forming peptide alamethicin. Drug Metab Disp 28:560-566.
17. Gertz M, Kilford PJ, Houston JB and Galetin A (2008) Drug lipophilicity and microsomal protein concentration as determinants in the prediction of the fraction unbound in microsomal incubations. Drug Metab Disp 36:535-542.
18. Guillemette C (2003) Pharmacogenetics of human UDP- glucuronosyltransferase enzymesM. Pharmacogenet J 3:136-158.
19. Ito K, Brown HS and Houston JB (2005a) Database analyses for the prediction of in vivo drug-drug interactions from in vitro data. Br J Clin Pharmacol 57:473-486.
20. Ito K, Hallifax D, Obach RS and Houston JB (2005b) Impact of parallel metabolic pathways of drug elimination and multiple cytochrome P450 involvement on drug - drug interactions: CYP2D6 paradigm. Drug Metab Disp 33:837-844.
21. Ito K, Iwatsubo T, Kanamitsu S, Ueda K, Suzuki H and Sugiyama Y (1998) Prediction of pharmacokinetic alterations caused by drug - drug interactions: metabolic interaction in the liver. Pharmacol Rev 50:387-411.
22. Kerdpin O, Elliot DJ, Mackenzie PI and Miners JO (2006) Sulfinpyrazone C-glucuronidation is catalyzed selectively by human UDP-glucuronosyltransferase 1A9 (UGT1A9). Drug Metab Disp 34:1950-1953.
23. Kiang TKL, Ensom MHH and Chang TKH (2005) UDP-Glucuronosyltransferases and clinical drug-drug interactions. Pharmacol Ther 106:97-132.
24. Kirkwood LC, Nation RL and Somogyi AA (1998) Glucuronidation of dihydrocodeine by human liver microsomes and the effect of inhibitors. Clin Exp Pharmacol Physiol 25:266-270.
25. Kumar S, Samuel K, Subramanian R, Braun MP, Stearns RA, Chiu SH, Evans DC and Baillie TA (2002) Extrapolation of diclofenac clearance from in vitro microsomal metabolism data: role of acyl glucuronidation and sequential oxidative metabolism of the acyl glucuronide. J Pharmacol Exp Ther 303:969-978.
26. Lewis LD, Benin A, Szumlanski CL, Otterness DM, Lennard L and Weinshilboum RM (1997) Olsalazine and 6-mercaptopurine related bone marrow suppression: a possible drug-drug interaction. Clin Pharmacol Ther 62:464-475.
27. Mackenzie PI, Bock KW, Burchell B, Guillemette C, Iyanagi T, Miners JO, Owens IS and Nebert DW (2005) Nomenclature update for the mammalian UDP glycosyltransferase gene superfamily. Pharmacogenet Genomics 15:677-685.
28. McLure JA, Miners JO and Birkett DJ (2000) Nonspecific binding of drugs to human liver microsomes. Br J Clin Pharmacol 49:453-461.
29. Miners JO, Knights KM, Houston JB and Mackenzie PI (2006) In vitro - in vivo correlation for drugs cleared by glucuronidation: pitfalls and promises. Biochem Pharmacol 71:1531-1539.
30. Miners JO, Lillywhite KJ, Yoovathaworn K, Pongmarutai M and Birkett DJ (1990) Characterisation of paracetamol UDP-glucuronosyltransferase activity in human liver microsomes. Biochem Pharmacol 40:595-600.
31. Miners JO and Mackenzie PI (1991) Drug glucuronidation in humans. Pharmacol Ther 51:347-369.
32. Miners JO, McKinnon RA and Mackenzie PI (2002) Genetic polymorphism of UDP-glucuronosyltransferases and their functional significance. Toxicology 181-182:453-456.
33. Miners JO, Smith PA, Sorich MJ, McKinnon RA and Mackenzie PI (2004) Predicting human drug glucuronidation parameters: applications of in vitro and in silico modeling approaches. Annu Rev Pharmacol Toxicol 44:1-25.
34. Miners JO, Valente L, Lillywhite KJ, Mackenzie PI, Burchell B, Baguley BC and Kestell P (1997) Preclinical prediction of factors influencing the elimination of dimethylxanthenone-4-acetic acid, a new anticancer drug. Cancer Res 57:284-289.
35. Ogilvie BW, Zhang D, Li W, Rodrigues AD, Gipson AE, Holsapple J, Toren P and Parkinson A (2006) Glucuronidation converts gemfibrozil to a potent, metabolism-dependent inhibitor of CYP2C8: implications for drug-drug interactions. Drug Metab Disp 34:191-197.
36. Oleson L and Court MH (2008) Effect of the β-glucuronidase inhibitor saccharolactone on glucuronidation by human liver microsomes and recombinant UDP-glucuronosyltransferases. J Pharm Pharmacol 60:1175-1182.
37. Polasek TM and Miners JO (2007) In vitro approaches to investigate mechanism-based inactivation of cytochromes P450. Exp Opin Drug Metab Toxicol 3:321-329.
38. Riley RJ, McGinnity DF and Austin RP (2005) A unified model for predicting human hepatic, metabolic clearance from in vitro clearance data in hepatocytes and microsomes. Drug Metab Disp 33:1304-1311.
39. Rowland A, Elliot DJ, Knights KM, Mackenzie PI, and Miners JO (2008b) The albumin effect and in vitro - in vivo extrapolation: sequestration of long chain unsaturated fatty acids enhances phenytoin hydroxylation by human liver microsomes and recombinant cytochrome P450 2C9. Drug Metab Disp 36:870-877.
40. Rowland A, Elliot DJ, Williams JA, Mackenzie PI, Dickinson RG and Miners JO (2006) In vitro characterization of lamotrigine N2-glucuronidation and the lamotrigine - valproic acid interaction. Drug Metab Disp 34:1055-1063.
41. Rowland A, Gaganis P, Elliot DJ, Mackenzie PI, Knights KM and Miners JO (2007) Binding of inhibitory fatty acids is responsible for enhancement of UDP-glucuronosyltransferase 2B7 (UGT2B7) activity by albumin. J Pharmacol Exp Ther 321:137-147.
42. Rowland A, Knights KM, Mackenzie PI, and Miners JO (2008a) The albumin effect and drug glucuronidation: bovine serum albumin and fatty acid free human serum albumin enhance the glucuronidation of UGT1A9 substrates but not UGT1A1 and UGT1A6 activities. Drug Metab Disp 36:1056-1062.
43. Sahai J, Gallicano K, Pakuts A and Cameron DW (1994) Effect of fluconazole on zidovudine pharmacokinetics in patients infected with human immunodeficiency virus. J Infec Dis 169:1103-1107.
44. Shitara Y, Hirano M, Sato H and Sugiyama Y (2004) Gemfibrozil and its glucuronide inhibit the organic anion transporting peptide 2 (OATP2/OATP1B1:SLC21A6)-mediated hepatic uptake and CYP2C8-mediated metabolism of cerivastatin: analysis of the mechanism of the clinically relevant drug-drug interaction between cerivastatin and gemfibrozil. J Pharmacol Expl Ther 311:228-236.
45. Soars MG, Burchell B and Riley RJ (2002) In vitro analysis of human drug glucuronidation and prediction of in vivo metabolic clearance. J Pharmacol Exp Ther 301:382-390.
46. Soars MG, Ring BJ and Wrighton SA (2003) The effect of incubation conditions on the enzyme kinetics of UDP-glucuronosyltransferases. Drug Metab Disp 31:762-767.
47. Stone AN, Mackenzie PI, Galetin A, Houston JB and Miners JO (2003) Isoform selectivity and kinetics of morphine 3- and 6-glucuronidation by human UDP-glucuronosyltransferases: evidence for atypical glucuronidation kinetics by UGT2B7. Drug Metab Disp 31:1086-1089.
48. Sykes MJ, Sorich MJ and Miners JO (2006) Molecular modelling approaches for the prediction of the non-specific binding of drugs to human liver microsomes. J Chem Inf Model 46:2661-2673.
49. Tsoutsikos P, Miners JO, Stapleton A, Thomas T, Sallustio BC and Knights KM (2004) Evidence that unsaturated fatty acids are potent inhibitors of renal UDP-glucuronosyltransferases: kinetic studies using human kidney cortical microsomes and recombinant UGT1A9 and UGT2B7. Biochem Pharmacol 67:191-199.
50. Tukey RH and Strassburg CP (2000) Human UDP-glucuronosyltransferases: metabolism, expression and disease. Ann Rev Pharmacol Toxicol 40:581-616.
51. Uchaipichat V, Elliot DJ, Mackenzie PI and Miners JO (2006b) Selectivity of substrate (trifluoperazine) and inhibitor (amitriptyline, androsterone, canrenoic acid, hecogenin, phenylbutazone, quinidine, quinine and sulfinpyrazone) probes for human UDP-glucuronosyltransferases. Drug Metab Disp 34:449-456.
52. Uchaipichat V, Galetin A, Houston JB, Mackenzie PI, Williamd JA and Miners JO (2008) Kinetic modeling of the interactions between 4-methylumbelliferone, 1-naphthol and zidovudine glucuronidation by UDP-glucuronosyltransferase 2B7 (UGT2B7) provides evidence for multiple substrate and effector binding sites. Molec Pharmacol 74:1152-1162.
53. Uchaipichat V, Mackenzie PI, Guo X-H, Gardner-Stephen D, Galetin A, Houston JB and Miners JO (2004) Human UDP-glucuronosyltransferases: isoform selectivity and kinetics of 4-methylumbelliferone and 1-naphthol glucuronidation, effects of organic solvents, and inhibition by diclofenac and probenecid. Drug Metab Disp 32:413-423.
54. Uchaipichat V, Winner LK, Elliot DJ, Mackenzie PI, Williams JA and Miners JO (2006a) Quantitative prediction of inhibitory interactions involving glucuronidated drugs from in vitro data: the effect of fluconazole on zidovudine glucuronidation. Br J Clin Pharmacol 61:427-439.
55. Udomuksorn W, Elliot DJ, Lewis BC, Mackenzie PI, Yoovathaworn K and Miners JO (2007) Influence of mutations associated with the Gilbert and Crigler-Najjar type II syndromes on the glucuronidation of bilirubin and other UDP-glucuronosyltransferase 1A substrates. Pharmacogenet Genomics 17:1017-1029.
56. Wen Z, Tallman MN, Ali SY and Smith PC (2007) UDP-Glucuronosyltransferase 1A1 is the principal enzyme responsible for etoposide glucuronidation in human liver and intestinal microsomes: structural characterization of phenolic and alcoholic glucuronides of etoposide and estimation of enzyme kinetics. Drug Metab Disp 35:371-380.
57. Williams JA, Hyland R, Jones BC, Smith DA, Hurst S, Goosen TC, Peterkin V, Koup JR and Ball SE (2004) Drug-drug interactions for UDP- glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab Disp 32:1201-1208.
58. Williams JA, Ring BJ, Cantrell VE, Campanale K, Jones DR, Hall SD and Wrighton SA (2002) Differential modulation of UDP-glucuronosyltransferase 1A1 (UGT1A1) catalyzed estradiol 3-glucuronidation by the addition of UGT1A1 substrates and other compounds to human liver microsomes. Drug Metab Disp 30:1266-1273.